Heterostilbene Carbamates with Selective and Remarkable Butyrylcholinesterase Inhibition: Computational Study and Physico-Chemical Properties
2025
Anamarija Raspudić | Ilijana Odak | Milena Mlakić | Antonija Jelčić | Karla Bulava | Karla Karadža | Valentina Milašinović | Ivana Šagud | Paula Pongrac | Dora Štefok | Danijela Barić | Irena Škorić
This manuscript reports the synthesis and characterization of 19 novel heterostilbene carbamates, designed as selective butyrylcholinesterase (BChE) inhibitors with potential applications in the treatment of neurodegenerative disorders, particularly Alzheimer’s disease. The compounds were synthesized from resveratrol analogs, and their structures were confirmed by NMR spectroscopy, high-resolution mass spectrometry (HRMS), and single-crystal X-ray diffraction for selected derivatives (compounds <b>1</b> and <b>4</b>). In vitro assays demonstrated high selectivity toward BChE over acetylcholinesterase (AChE), with compound <b>16</b> exhibiting exceptional inhibitory activity (IC<sub>50</sub> = 26.5 nM). Furthermore, compound <b>16</b> showed moderate anti-inflammatory effects by inhibiting LPS-stimulated TNF-α production in peripheral blood mononuclear cells. In silico ADME(T) profiling revealed favorable pharmacokinetic properties and low mutagenic potential for the majority of compounds. Molecular docking and molecular dynamics simulations confirmed stable binding interactions within the BChE active site. These results highlight heterostilbene carbamates as promising lead structures for developing novel therapeutic agents targeting neurodegenerative diseases.
显示更多 [+] 显示较少 [-]